Nuvectis Pharma FY2023 net loss $22.3M; cash $19.1M; NXP800 data update expected March 2024

Nuvectis Pharma, Inc.

Cash and cash equivalents $19.1M at Dec 31, 2023, down from $20.0M at Dec 31, 2022.
Net loss for FY2023 was $22.3M vs $19.1M in FY2022; includes $4.7M non-cash stock compensation.
R&D expenses increased to $15.4M from $13.2M; G&A increased to $7.5M from $6.0M.
NXP800 Phase 1b preliminary data update expected in March 2024 for platinum-resistant ARID1a-mutated ovarian cancer.
NXP900 Phase 1a dose escalation initiated; multiple clinical data readouts expected in 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Nuvectis Pharma, Inc. reported the fiscal year ended December 31, 2023 results: net income $22.3 million.

Period: the fiscal year ended December 31, 2023
Net income: $22.3 million
Result: reported results

Exact text from the filing

The Company's net loss was $22.3 million for the year ended December 31, 2023, compared to $19.1 million for the year ended December 31, 2022

View on SEC.gov

708 earnings releases filed in the last 30 days. Browse all earnings releases →

Nuvectis Pharma, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-030773

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.